<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659334</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00001127</org_study_id>
    <secondary_id>5R01NS034608</secondary_id>
    <secondary_id>OHSU-1127</secondary_id>
    <nct_id>NCT00659334</nct_id>
  </id_info>
  <brief_title>Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation</brief_title>
  <official_title>Multi-disciplinary Study: MR, Histologic and EM Imaging of Intravenous Superparamagnetic Crystalline Particles (Combidex) to Brain, Intra-cerebral Tumors and in CNS Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combidex (ferumoxtran-10) is an ultra-small iron oxide particle covered with a sugar coating.
      It has been evaluated as an MRI contrast agent for use in imaging well perfused organs such
      as the liver and spleen and for imaging lymph nodes. In this study, Combidex is being used to
      compare the standard imaging agent, Gadolinium, in imaging brain tumors and the area adjacent
      to the tumor location. Combidex may provide the ability to better see brain tumors and
      inflammatory lesions on magnetic resonance imaging (MRI) scans. Combidex may be useful in its
      ability to cross blood vessels into brain tumors, and because of its size and ability to get
      into the area next to brain tumors, could assist in the treatment of brain tumors with other
      drugs in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects are recruited as patients in one of the neurology, neurosurgery or neuro-oncology
      clinics at OHSU. There are four groups of the study:

        -  Subjects receive the combidex infusion only.

        -  Subjects receive Combidex and undergo a previously schedule neurosurgery.

        -  Subjects undergo surgery only and provide a sample of their tumor tissue to be used in
           pathology studies of Combidex.

        -  Subjects with MS or stroke are invited to participate in receiving Combidex to evaluate
           the effectiveness of enhancing the area of damage within the brain.

      Subjects are deemed eligible for the study and undergo a baseline MRI within 28 days of
      receiving Combidex. Subjects receiving Combidex are admitted for a half day into the Oregon
      Clinical &amp; Translational Research Institute(OCTRI). Combidex is infused I.V. over 30 minutes.
      Subjects are monitored for side effects and are discharged within about 5 hours after the
      infusion, if no complications have been noted. Subjects return 24 hours after the infusion
      for a post infusion MRI scan and return again to one of the neurology clinics for one month
      follow-up. Subjects enrolled in group 2 undergo surgery 1-2 days after the Combidex infusion
      and also undergo a 24 post infusion MRI and return for one month follow-up. These subjects
      are also followed closely by the neurosurgical physician during the course of follow-up.
      Subjects enrolled in group 3 only undergo surgery and agree to have a piece of their tumor
      resection or biopsy donated for use in the study. Group 4 is the same as group 1, except the
      patient population includes multiple sclerosis and stroke instead of patients with brain
      tumors.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    AMAG not continuing with Combidex, the study drug
  </why_stopped>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experience Optimal Imaging in Adult and Pediatric Brain Tumors to Establish Timing and Sequencing Parameters of Combidex.</measure>
    <time_frame>24 hours (some patients between 3 and 72 hours) after administration of Combidex</time_frame>
    <description>Signal intensity change in participants with Pre and 24 hours Post Combidex on T1, T2, T2* MRI sequences will be assessed (some patients undergo scans at 3 and 72 hours in order to assess radiographic changes at these time points). Combidex will be administered in dose 2.6 mg/kg in adults with high and low grade gliomas, metastases, meningiomas, and PNET; and in pediatric patients with astrocytomas grade i-iv, brain stem gliomas, ependymomas, CNS germ cell tumors, and PNET.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the Cellular Uptake of Particles in Brain Tumor Patients by Comparing Imaging Results With Histology and Electron Microscopic Examination of Biopsy Tissue</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Combidex Imaging in Brain Tumor Patients, With Other CNS Inflammatory Lesions Such as Multiple Sclerosis and Stroke.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Pre- and Post-op Gd Enhanced MRI Combidex Enhanced MR Imaging Done Pre-, Intra- and Post-operatively, to Assess the Degree of Resection and Residual Tumor.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Brain Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adults with brain tumor to receive Combidex infusion only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adults with brain tumors to receive Combidex infusion and neurosurgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adults with brain tumors to receive neurosurgery only (NO Combidex)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children with brain tumors to receive Combidex only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children with brain tumors to receive Combidex and neurosurgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Children with brain tumors to receive neurosurgery only, NO Combidex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adults with Inflammatory lesions (stroke or MS) to receive Combidex only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxtran-10 (Combidex)</intervention_name>
    <description>2.6 mg/kg</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <other_name>Combidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neurosurgery</intervention_name>
    <description>neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Brain tumor or CNS inflammatory lesion including stroke or MS

          -  5 yrs old or older

          -  Able to undergo MRI without general anesthesia

          -  Agree to be followed for 1 month following infusion of Combidex

          -  Sign a written informed consent

          -  If female and of child-bearing potential, be postmenopausal, sterile, or be on birth
             control for 1 month prior to study

          -  Must have a pre-treatment MRI within 28 days before study

        Exclusion Criteria:

          -  Clinically significant signs of uncal herniation

          -  Allergy to study drug, Combidex

          -  Hepatic insufficiency

          -  Stage IV or V renal insufficiency

          -  If female, pregnant or lactating

          -  Require anesthesia for MRI scanning

          -  Hemachromatosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward A Neuwelt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2008</study_first_submitted>
  <study_first_submitted_qc>April 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <results_first_submitted>May 15, 2012</results_first_submitted>
  <results_first_submitted_qc>October 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2012</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Edward Neuwelt</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Combidex</keyword>
  <keyword>Diagnostic imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects are recruited as patients in one of the neurology, neurosurgery or neuro-oncology clinics at OHSU.</recruitment_details>
      <pre_assignment_details>There are seven groups in the study. In Groups 1(adults) and 4(pediatric) subjects receive the Combidex infusion only. In Groups 2(adult) and 5(pediatrics) subjects receive Combidex and undergo neurosurgery. In Groups 3(adult) and 6(pediatric) subjects undergo surgery with tissue exam; and in Group 7(adult only) subjects with MS or stroke.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combidex Only (Group 1)</title>
          <description>Adults with brain tumor to receive Combidex infusion only</description>
        </group>
        <group group_id="P2">
          <title>Combidex and Neurosurgery (Group 2)</title>
          <description>Adults with brain tumors to receive Combidex infusion and neurosurgery</description>
        </group>
        <group group_id="P3">
          <title>Neurosurgery Only (Group 3)</title>
          <description>Adults with brain tumors to receive neurosurgery only (NO Combidex)</description>
        </group>
        <group group_id="P4">
          <title>Combidex Only (Group 4)</title>
          <description>Children with brain tumors to receive Combidex only</description>
        </group>
        <group group_id="P5">
          <title>Combidex and Neurosurgery (Group 5)</title>
          <description>Children with brain tumors to receive Combidex and neurosurgery</description>
        </group>
        <group group_id="P6">
          <title>Neurosurgery Only (Group 6)</title>
          <description>Children with brain tumors to receive neurosurgery only, NO Combidex</description>
        </group>
        <group group_id="P7">
          <title>Inflammatory Lesions (Group 7)</title>
          <description>Adults with Inflammatory lesions (stroke or MS) to receive Combidex only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38">8 Screen failures</participants>
                <participants group_id="P2" count="36">5 Screen failures</participants>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="20">1 screen failure</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combidex Only (Group 1)</title>
          <description>Adults with brain tumor to receive Combidex infusion only</description>
        </group>
        <group group_id="B2">
          <title>Combidex and Neurosurgery (Group 2)</title>
          <description>Adults with brain tumors to receive Combidex infusion and neurosurgery</description>
        </group>
        <group group_id="B3">
          <title>Neurosurgery Only (Group 3)</title>
          <description>Adults with brain tumors to receive neurosurgery only (NO Combidex)</description>
        </group>
        <group group_id="B4">
          <title>Combidex Only (Group 4)</title>
          <description>Children with brain tumors to receive Combidex only</description>
        </group>
        <group group_id="B5">
          <title>Combidex and Neurosurgery (Group 5)</title>
          <description>Children with brain tumors to receive Combidex and neurosurgery</description>
        </group>
        <group group_id="B6">
          <title>Neurosurgery Only (Group 6)</title>
          <description>Children with brain tumors to receive neurosurgery only, NO Combidex</description>
        </group>
        <group group_id="B7">
          <title>Inflammatory Lesions (Group 7)</title>
          <description>Adults with Inflammatory lesions (stroke or MS) to receive Combidex only</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="21"/>
            <count group_id="B8" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="13.2"/>
                    <measurement group_id="B2" value="48.4" spread="12.8"/>
                    <measurement group_id="B3" value="45.4" spread="14.2"/>
                    <measurement group_id="B4" value="14.7" spread="1.4"/>
                    <measurement group_id="B5" value="14.1" spread="0"/>
                    <measurement group_id="B7" value="43.0" spread="15.3"/>
                    <measurement group_id="B8" value="48.8" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience Optimal Imaging in Adult and Pediatric Brain Tumors to Establish Timing and Sequencing Parameters of Combidex.</title>
        <description>Signal intensity change in participants with Pre and 24 hours Post Combidex on T1, T2, T2* MRI sequences will be assessed (some patients undergo scans at 3 and 72 hours in order to assess radiographic changes at these time points). Combidex will be administered in dose 2.6 mg/kg in adults with high and low grade gliomas, metastases, meningiomas, and PNET; and in pediatric patients with astrocytomas grade i-iv, brain stem gliomas, ependymomas, CNS germ cell tumors, and PNET.</description>
        <time_frame>24 hours (some patients between 3 and 72 hours) after administration of Combidex</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combidex Only (Group 1)</title>
            <description>Adults with brain tumor to receive Combidex infusion only</description>
          </group>
          <group group_id="O2">
            <title>Combidex and Neurosurgery (Group 2)</title>
            <description>Adults with brain tumors to receive Combidex infusion and neurosurgery</description>
          </group>
          <group group_id="O3">
            <title>Neurosurgery Only (Group 3)</title>
            <description>Adults with brain tumors to receive neurosurgery only (NO Combidex)</description>
          </group>
          <group group_id="O4">
            <title>Combidex Only (Group 4)</title>
            <description>Children with brain tumors to receive Combidex only</description>
          </group>
          <group group_id="O5">
            <title>Combidex and Neurosurgery (Group 5)</title>
            <description>Children with brain tumors to receive Combidex and neurosurgery</description>
          </group>
          <group group_id="O6">
            <title>Neurosurgery Only (Group 6)</title>
            <description>Children with brain tumors to receive neurosurgery only, NO Combidex</description>
          </group>
          <group group_id="O7">
            <title>Inflammatory Lesions (Group 7)</title>
            <description>Adults with Inflammatory lesions (stroke or MS) to receive Combidex only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience Optimal Imaging in Adult and Pediatric Brain Tumors to Establish Timing and Sequencing Parameters of Combidex.</title>
          <description>Signal intensity change in participants with Pre and 24 hours Post Combidex on T1, T2, T2* MRI sequences will be assessed (some patients undergo scans at 3 and 72 hours in order to assess radiographic changes at these time points). Combidex will be administered in dose 2.6 mg/kg in adults with high and low grade gliomas, metastases, meningiomas, and PNET; and in pediatric patients with astrocytomas grade i-iv, brain stem gliomas, ependymomas, CNS germ cell tumors, and PNET.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O7" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Cellular Uptake of Particles in Brain Tumor Patients by Comparing Imaging Results With Histology and Electron Microscopic Examination of Biopsy Tissue</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Combidex Imaging in Brain Tumor Patients, With Other CNS Inflammatory Lesions Such as Multiple Sclerosis and Stroke.</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Pre- and Post-op Gd Enhanced MRI Combidex Enhanced MR Imaging Done Pre-, Intra- and Post-operatively, to Assess the Degree of Resection and Residual Tumor.</title>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Other adverse events were collected/assessed, but none affected over 5% of the patient population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combidex Only (Group 1)</title>
          <description>Adults with brain tumor to receive Combidex infusion only</description>
        </group>
        <group group_id="E2">
          <title>Combidex and Neurosurgery (Group 2)</title>
          <description>Adults with brain tumors to receive Combidex infusion and neurosurgery</description>
        </group>
        <group group_id="E3">
          <title>Neurosurgery Only (Group 3)</title>
          <description>Adults with brain tumors to receive neurosurgery only (NO Combidex)</description>
        </group>
        <group group_id="E4">
          <title>Combidex Only (Group 4)</title>
          <description>Children with brain tumors to receive Combidex only</description>
        </group>
        <group group_id="E5">
          <title>Combidex and Neurosurgery (Group 5)</title>
          <description>Children with brain tumors to receive Combidex and neurosurgery</description>
        </group>
        <group group_id="E6">
          <title>Neurosurgery Only (Group 6)</title>
          <description>Children with brain tumors to receive neurosurgery only, NO Combidex</description>
        </group>
        <group group_id="E7">
          <title>Inflammatory Lesions (Group 7)</title>
          <description>Adults with Inflammatory lesions (stroke or MS) to receive Combidex only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Post-Op Infection</sub_title>
                <description>Post-Op infection from craniotomy.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cerebellar Infraction</sub_title>
                <description>Cerebellar infraction in the left hemisphere.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early trial termination due to study drug Combidex no longer manufactured.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Edward Neuwelt</name_or_title>
      <organization>OHSU Knight Cancer Institute</organization>
      <phone>503-494-5626</phone>
      <email>neuwelte@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

